ClinicalTrials.Veeva

Menu

Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD)

Johns Hopkins University logo

Johns Hopkins University

Status

Completed

Conditions

COPD

Treatments

Other: High flow of room air
Other: Oxygen

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01764165
NA_00040333 (Other Identifier)
R01HL105546-01

Details and patient eligibility

About

This research is being conducted to examine the effects of nasal insufflation of warm and humidified air through a small nasal cannula on sleep, breathing pulmonary function, and daytime exercise capability.

Full description

Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity including substantial daytime fatigue exertional intolerance and ventilatory impairment, which hits a nadir in the morning. Nocturnal disturbances in sleep and breathing are common in COPD, although the impact of these disturbances on COPD morbidity remains largely unknown. The hypothesis is that COPD induces specific sleep and breathing disturbances that remain a substantial source of morbidity in this disorder.

Current therapy for treating nocturnal disturbances in sleep and breathing in COPD including nocturnal oxygen has failed to improve morning fatigue and pulmonary function. This study promises to significantly alter our approach to the diagnosis and management of sleep disordered breathing in COPD.

Enrollment

52 patients

Sex

All

Ages

21 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Consenting adults over the age of 21
  • BMI < 40 kg/m2

Exclusion criteria

  • Diagnosed with sleep apnea (apnea and hypopneas of >10 events/hr).
  • A sleep efficiency of <30%, or a prior diagnosis of disorders that impair sleep architecture.
  • Unstable cardiovascular disease (decompensated heart failure, myocardial infarction within the past 3 months, revascularization procedure within the past 3 months, unstable arrhythmias, uncontrolled hypertension (BP > 190/110)).
  • Severe renal insufficiency requiring dialysis.
  • Liver cirrhosis.
  • A recent acute illness in a 6 weeks period prior to the sleep studies.
  • We will exclude subjects with severe daytime hypoxemia (Oxyhemoglobin saturation (SaO2) <80% or partial pressure of oxygen (PaO2) <55 mmHg at rest).
  • Chronic use of sedatives or respiratory depressants that would affect sleep quality (e.g., benzodiazepines or other hypnotics or narcotics).
  • Pregnancy.
  • Tracheostomy or other significant oropharyngeal or nasopharyngeal surgery, in the last 6 months.
  • Narcolepsy and other neurological disorders such as Parkinson's Disease.
  • Severe hepatic insufficiency.
  • Bleeding disorders or Coumadin use.
  • Allergy to lidocaine or benzocaine.
  • Language/dementia/psychiatric issues - the participant must be able to provide consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

52 participants in 2 patient groups

oxygen
Active Comparator group
Description:
nocturnal oxygen of 2 L/min
Treatment:
Other: Oxygen
High Flow of room air
Experimental group
Description:
Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
Treatment:
Other: High flow of room air

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems